Factors associated with motor fluctuations and dyskinesia in Parkinson disease: Potential role of a new melevodopa plus Carbidopa formulation (Sirio)

Clinical Neuropharmacology

Volumn 33, Issue 4, 2010, Pages 198-203

  Stocchi, Fabrizio ^a   Marconi, Stefano ^b  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b CHIESI FARMACEUTICI S P A   (Italy)

Author keywords

dyskinesia; latency to B "on"; melevodopa; motor complication

Indexed keywords

CARBIDOPA; LEVODOPA METHYL ESTER; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DYSKINESIA; DYSTONIA; HUMAN; MUSCLE RIGIDITY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; STOMACH EMPTYING;

ANTIPARKINSON AGENTS; BIOLOGICAL AVAILABILITY; CARBIDOPA; DELAYED-ACTION PREPARATIONS; DOPAMINE AGONISTS; DRUG COMBINATIONS; DYSKINESIA, DRUG-INDUCED; DYSKINESIAS; FEMALE; HUMANS; HYPERKINESIS; LEVODOPA; MALE; PARKINSON DISEASE; SOLUBILITY; TIME FACTORS;

EID: 77955172381     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181de8924     Document Type: Review

References (32)

1. Koller WC, Hutton JT, Tolosa E, et al. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology 1999;53(5):1012-1019.
2. Rao SS, Hofmann LA, Shakil A. Parkinson's disease: diagnosis and treatment. Am Fam Physician 2006;74(12):2046-2054.
3. Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004;19(9): 997-1005.
4. Merims D, Djaldetti R, Melamed E. Waiting for ON: a major problem in patients with Parkinson disease and ON/OFF motor fluctuations. Clin Neuropharmacol 2003;26(4):196-198.
5. Miyasaki JM, Martin W, Suchowersky O, et al. Practice parameter: initiation oftreatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002;58(1):11-17.
6. Weintraub D, Comella CL, Horn S. Parkinson's disease-part 2: treatment of motor symptoms. Am JManag Care 2008;14(2):S49-S58.
7. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 2007;6(9):826-829.
8. Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007;356(1):39-6.
9. Pahwa R, Factor SA, Lyons KE, et al. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66(7):983-995.
10. Antonini A. Management of Parkinson's disease. European Neurological Disease 2007:42-44.
11. Stocchi F. The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations. Expert Opin Pharmacother 2006;7(10):1399-1407.
12. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. NEngl J Med 2004;351(24):2498-2508.
13. Stocchi F, Fabbri L, Vecsei L, et al. Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease. Clin Neuropharmacol 2007;30(1):18-24.
14. Djaldetti R, Inzelberg R, Giladi N, et al. Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease. Mov Disord 2002;17(2):297-302.
15. Nyholm D, Lennernas H. Irregular gastrointestinal drug absorption in Parkinson's disease. Expert Opin Drug Metab Toxicol 2008;4(2): 193-203.
16. Stocchi FR, Ruggieri S, Bramante L, et al. Intrajejunal infusion of L-dopa methylester. In: European Conference on Parkinson's Disease and Extrapyramidal Disorders, 1990. Rome, Italy.
17. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet 2004; 363(9423):1783-1793.
18. Fabbrini GM, Mouradian MM, Juncos JL, et al. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part I. Ann Neurol 1988;24:366-371.
19. Murdoch D, Cheer SM, Wagstaff AJ. Management of Parkinson disease: defining the role of ropinirole. Dis Manag Clin Outcomes 2004;12(1):39-54.
20. Jankovic J, Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs 2007;21(8):677-692.
21. Bonuccelli U. Comparing dopamine agonists in Parkinson's disease. Curr Opin Neurol 2003;16(suppl 1):S13-S19.
22. van Laar T. Levodopa-induced response fluctuations in patients with Parkinson's disease. CNS Drugs 2003;17(7):475-489.
23. Blanchet PJ, Papa SM, Metman LV, et al. Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease. Neurosci Biobehav Rev 1997;21(4):447-453.
24. Stocchi F, Vacca L, Ruggieri S, et al. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 2005;62(6):905-910.
25. Yeh KC, August TF, Bush DF, et al. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology 1989;39(suppl 2):25-38.
26. Dupont E, Andersen A, Boas J, et al. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol Scand 1996; 93(1):14-20.
27. Stocchi F, Quinn NP, Barbato L, et al. Comparison between a fast and a slow release preparation of levodopa and a combination of the two: a clinical and pharmacokinetic study. Clin Neuropharmacol 1994; 17(1):38-44.
28. Hauser RA, Panisset M, Abbruzzese G, et al. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Mov Disord 2009;24(4):541-550.
29. Blindauer K, Shoulson I, Oakes D, et al. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch Neurol 2006;63:210-216.
30. Steiger MJ, Stocchi F, Carta A, et al. The clinical efficacy of oral levodopa methyl ester solution in reversing afternoon "off" periods in Parkinson's disease. Clin Neuropharmacol 1991;14(3):241-244.
31. Fabbri L, Martignoni E, for the European Study Group. Clinical efficacy of single morning doses of two liquid formulations of levodopa: levodopa/benserazide dispersible and melevodopa/carbidopa effervescent. Neurological Sciences 2003;24(suppl 1):S46.
32. Sirio Prescribing Information. Chiesi Farmaceutici S.p.A. VP, Parma, Italy, Sirio: summary of product characteristics, 2007.